In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dealmaking Trends, Part II: The Valuation Divide

Executive Summary

Late-stage products are more valuable than ever, as products and as licensing currency. Drug originators, for example, can generate the same kinds of partner funding and commitment from mere co-promotions that were once available only from joint ventures or outright exclusive out-licensing deals. But no one except Big Pharma seems to reap the rewards on Wall Street--largely because investors believe that new entrants can't overcome the increasing barriers to the drug business. With their shares in the doghouse, biotechs who have successfully launched products are struggling to craft strategies that will prove their staying power and long-term value.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel